
    
      This study will be a single centre, open-label study. It will comprise of 2 single oral doses
      with at least a 14-day washout between doses. Following the first dose subjects will be
      discharged from the unit for the remainder of the washout period. Subjects will be
      re-admitted to the unit on Day -1 (Period 2) and following an overnight fast they will be
      administered the second dose on Day 1 (Period 2). Subjects will be discharged from the unit
      following the 168 h PK blood draw.
    
  